Literature DB >> 30697461

Utility of metabolic heterogeneity factor in differentiating malignant versus benign parotid uptake on 18F FDG PET-CT.

Ramin Alipour1,2, Steven Smith1, Sandeep K Gupta1,2.   

Abstract

Differentiation of benign and malignant parotid uptake on Fluorine 18 Fluro-Deoxy-Glucose Positron Emission Tomography-Computed Tomography (18F FDG PET-CT) is of paramount importance due to the poor prognosis of the later but usual quantitative measures such as standardized uptake value (SUV) are not reliable for this purpose. Metabolic heterogeneity, being a characteristic of malignant tumors, would potentially be able to make this distinction. In this study, seventy-one FDG-avid parotid lesions were retrospectively separated histologically into benign and malignant groups. The heterogeneity factor (HF) of all the lesions was then calculated and compared between the two groups. There was significant difference in HF between malignant (median -0.17) and benign group (median -0.03); P=0.0006. On receiver operating characteristic (ROC) analysis, a cut-off value of ≤ -0.06 for HF was associated with the highest sensitivity and specificity (sensitivity and specificity of 94.6% and 60.0%, respectively-AUC=0.789; P=0.0001). Hence, it was concluded that HF is a reliable value in distinguishing benign from malignant parotid uptake on 18F FDG PET-CT.

Entities:  

Keywords:  18F FDG PET-CT; Heterogeneity factor; parotid malignancy

Year:  2018        PMID: 30697461      PMCID: PMC6334206     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  18 in total

Review 1.  18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer.

Authors:  Kristoff Muylle; Catherine Castaigne; Patrick Flamen
Journal:  Curr Opin Oncol       Date:  2005-05       Impact factor: 3.645

2.  Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.

Authors:  David Hadiprodjo; Timothy Ryan; Minh-Tam Truong; Gustavo Mercier; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2012-02       Impact factor: 3.959

Review 3.  Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake.

Authors:  Todd M Blodgett; Melanie B Fukui; Carl H Snyderman; Barton F Branstetter; Barry M McCook; Dave W Townsend; Carolyn C Meltzer
Journal:  Radiographics       Date:  2005 Jul-Aug       Impact factor: 5.333

4.  Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.

Authors:  Songji Zhao; Yuji Kuge; Takafumi Mochizuki; Toshiyuki Takahashi; Kunihiro Nakada; Masayuki Sato; Toshiki Takei; Nagara Tamaki
Journal:  J Nucl Med       Date:  2005-04       Impact factor: 10.057

5.  Clinical utility of 18F-FDG PET for patients with salivary gland malignancies.

Authors:  Jong-Lyel Roh; Chang Hwan Ryu; Seung-Ho Choi; Jae Seung Kim; Jeong Hyun Lee; Kyung-Ja Cho; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Nucl Med       Date:  2007-02       Impact factor: 10.057

6.  Dependence of FDG uptake on tumor microenvironment.

Authors:  Andrei Pugachev; Shutian Ruan; Sean Carlin; Steven M Larson; Jose Campa; C Clifton Ling; John L Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

7.  Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome.

Authors:  Janet F Eary; Finbarr O'Sullivan; Janet O'Sullivan; Ernest U Conrad
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

8.  Intratumoral metabolic heterogeneity of cervical cancer.

Authors:  Elizabeth A Kidd; Perry W Grigsby
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

9.  Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management.

Authors:  Sandip Basu; Mohamed Houseni; Abass Alavi
Journal:  Nucl Med Commun       Date:  2008-04       Impact factor: 1.690

10.  The histological structure of some human lung cancers and the possible implications for radiotherapy.

Authors:  R H THOMLINSON; L H GRAY
Journal:  Br J Cancer       Date:  1955-12       Impact factor: 7.640

View more
  2 in total

1.  Interobserver agreement of 18F-Fluorodeoxyglucose Positron-Emission Tomography combined with low-dose Computed Tomography for occult cancer screening in patients with unprovoked venous thromboembolism.

Authors:  Philippe Robin; Ravinder K Grewal; Pierre-Yves Le Roux; Grégoire Le Gal; Pierre-Yves Salaun
Journal:  Thromb Res       Date:  2020-01-30       Impact factor: 3.944

2.  Differentiation of soft tissue and bone sarcomas from benign lesions utilizing 18F-FDG PET/CT-derived parameters.

Authors:  Bo Chen; Hongbo Feng; Jinghui Xie; Chun Li; Yu Zhang; Shaowu Wang
Journal:  BMC Med Imaging       Date:  2020-07-25       Impact factor: 1.930

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.